ReviewChildren (Basel, Switzerland)2024
Macrophage Activation Syndrome in Children: Update on Diagnosis and Treatment.
Review in Children (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for macrophage activation syndrome in systemic juvenile idiopathic arthritis: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care.Pediatric investigation · 2026Review
- Macrophage activation syndrome in a 13-month-old child with systemic juvenile idiopathic arthritis mimicking sepsis: a diagnostic challenge and case report.Annals of medicine and surgery (2012) · 2026Article
- Machine learning of laboratory parameters to predict mortality risk in pediatric hemophagocytic lymphohistiocytosis: a retrospective single-center study.BMC pediatrics · 2026Article
- Paediatric rheumatologic emergencies: clinical spectrum and outcomes from a 3-year cohort study.European journal of pediatrics · 2026Article
- 2016 sJIA-MAS criteria and a step-up therapeutic approach in KD-MAS: insights from a combined cohort and literature review.RMD open · 2026Review
- Systemic Lupus Erythematosus with Nephritis: a Macrophage Activation Syndrome Heralding a New Disease Difficult to Diagnose.Mediterranean journal of hematology and infectious diseases · 2026Article
- Influencing factors of peripheral blood indicators on 30-day mortality risk in children with hemophagocytic lymphohistiocytosis based on weighted quantile sum regression: a single-center retrospective cohort study.Frontiers in pediatrics · 2026Article
- Ruxolitinib combined with corticosteroids for the successful treatment of kawasaki disease-associated macrophage activation syndrome: a case report.Frontiers in pediatrics · 2026Article
- Integration of Boruta algorithm and latent class analysis for risk factors of 30-day mortality in pediatric hemophagocytic lymphohistiocytosis based on peripheral blood indicators.Frontiers in pediatrics · 2026Article
- Juvenile Idiopathic Arthritis-The Rubik's Cube of Pediatric Rheumatology.Children (Basel, Switzerland) · 2025Article
- Hyperferritinemia and Macrophage Activation Syndrome in Septic Shock: Recent Advances with a Pediatric Focus (2020-2025).Children (Basel, Switzerland) · 2025Review
- Article
- Advancing multidisciplinary management of pediatric hyperinflammatory disorders.Frontiers in pediatrics · 2025Review
- Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.Children (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Macrophage activation syndrome (MAS) is potentially fatal; so, early diagnosis and timely treatment are essential. However, detecting MAS is sometimes challenging because its principal features can be observed in other pediatric diseases that cause severe inflammation. Cytokine storm due to immune dysregulation represents the clinical and laboratory features of MAS that are included in the diagnostic criteria. Most cases of MAS occur as an underlying condition worsens and progresses. Therefore, a patient with autoimmune or autoinflammatory disease who shows unexplained clinical deterioration despite appropriate management should be considered at high risk for MAS (i.e., occult MAS). The basic principles of treatment are control of triggering factors, supportive care, and relief of hyperinflammation. Systemic steroids and cyclosporine A are frequently used as a first-line treatment. For the treatment of refractory MAS, cytokine-specific biologic agents such as anakinra have recently become preferred over traditional immunosuppressive agents such as etoposide. MAS might be underrecognized in pediatric patients with infectious and inflammatory diseases due to its diverse clinical presentations. Clinical suspicion of MAS is of the utmost importance for early recognition of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.